bioMérieux – Third-Quarter 2019 Business Review
bioMérieux – First-Half 2019 Results
bioMérieux – Second-Quarter 2016 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its quarterly business review for the six months ended June 30, 2016.
bioMérieux enlarges its pathogen identification capability on VITEK® MS
With a database of more than 15,000 strains VITEK® MS improves clinical decision-making for infectious diseases.
bioMerieux Receives FDA Clearance for Expanded Use of VIDAS® B•R•A•H•M•S PCT™ Test for Managing Sepsis Patients with Elevated Risk of Mortality
Tracking PCT – a biomarker for bacterial infections – over time provides strong indication of likely mortality, enabling physicians to personalize care for high-risk patients.
bioMérieux acquires Hyglos
bioMérieux acquires Hyglos and expands its offering to the detection of endotoxins in pharmaceutical products.
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration
bioMérieux and the Lyon Civil Hospitals strengthen their collaboration and expand their partnership to include Claude Bernard University Lyon 1 Two joint research laboratories focused on a common goal: advancing medical research for the benefit of patients.
bioMérieux – First-Quarter 2016 Business Review
bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the three months ended March 31, 2016.
bioMérieux – 2015 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met yesterday under the chairmanship of Jean-Luc Belingard and approved the consolidated financial statements for the year ended December 31, 2015.